NO3019692T3 - - Google Patents
Info
- Publication number
- NO3019692T3 NO3019692T3 NO14742440A NO14742440A NO3019692T3 NO 3019692 T3 NO3019692 T3 NO 3019692T3 NO 14742440 A NO14742440 A NO 14742440A NO 14742440 A NO14742440 A NO 14742440A NO 3019692 T3 NO3019692 T3 NO 3019692T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749695P | 2013-01-07 | 2013-01-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3019692T3 true NO3019692T3 (pt) | 2018-06-16 |
Family
ID=51061430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO14742440A NO3019692T3 (pt) | 2013-01-07 | 2014-07-03 |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US9101624B2 (pt) |
| EP (1) | EP2941251B1 (pt) |
| JP (1) | JP6288726B2 (pt) |
| KR (1) | KR101885952B1 (pt) |
| CN (4) | CN105555272A (pt) |
| AP (1) | AP2015008628A0 (pt) |
| AU (1) | AU2013371624B2 (pt) |
| BR (1) | BR112015016282A2 (pt) |
| CA (1) | CA2897445C (pt) |
| CL (1) | CL2015001923A1 (pt) |
| CY (1) | CY1120026T1 (pt) |
| DK (1) | DK2941251T3 (pt) |
| EA (1) | EA033910B1 (pt) |
| ES (1) | ES2667958T3 (pt) |
| HK (1) | HK1224211A1 (pt) |
| HR (1) | HRP20180478T1 (pt) |
| HU (1) | HUE038594T2 (pt) |
| IL (1) | IL239802B (pt) |
| LT (1) | LT2941251T (pt) |
| MX (1) | MX369137B (pt) |
| NO (1) | NO3019692T3 (pt) |
| NZ (1) | NZ710720A (pt) |
| PE (1) | PE20151525A1 (pt) |
| PH (1) | PH12015501531B1 (pt) |
| PL (1) | PL2941251T3 (pt) |
| PT (1) | PT2941251T (pt) |
| RS (1) | RS57076B1 (pt) |
| SG (2) | SG10201705611PA (pt) |
| SI (1) | SI2941251T1 (pt) |
| WO (1) | WO2014107209A2 (pt) |
| ZA (1) | ZA201505545B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6407504B2 (ja) | 2012-09-21 | 2018-10-17 | アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法 |
| BR112015016282A2 (pt) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| EP3419593B1 (en) * | 2016-02-26 | 2022-03-23 | Celgene Corporation | Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia |
| JP7466308B2 (ja) | 2016-09-20 | 2024-04-12 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法 |
| WO2018085292A1 (en) * | 2016-11-02 | 2018-05-11 | Arog Pharmaceuticals, Inc. | Crenolanib for treating flt3 mutated proliferative disorders associated mutations |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES |
| US20220387362A1 (en) * | 2019-10-21 | 2022-12-08 | Rhizen Pharmaceuticals Ag | Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia |
| WO2022019998A1 (en) * | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| US20220047574A1 (en) * | 2020-08-15 | 2022-02-17 | Arog Pharmaceuticals, Inc. | Crenolanib for treating pdgfr alpha mutated proliferative disorders |
| EP4210847A1 (en) | 2020-09-02 | 2023-07-19 | Daniel Choi | Systems and methods for augmented reality environments and tokens |
| JP2023063189A (ja) * | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| US6960590B2 (en) | 2000-10-17 | 2005-11-01 | Merck & Co. Inc. | Orally active salts with tyrosine kinase activity |
| EP1330435B1 (en) * | 2000-10-31 | 2005-08-24 | Ciba SC Holding AG | Crystalline forms of fluvastatin sodium |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| WO2003024969A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
| IL161156A0 (en) | 2001-10-30 | 2004-08-31 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| AU2002360753B2 (en) | 2001-12-27 | 2008-08-21 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| JP4741948B2 (ja) | 2002-08-14 | 2011-08-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターおよびそれらの使用 |
| WO2004018419A2 (en) | 2002-08-23 | 2004-03-04 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| JPWO2004039782A1 (ja) | 2002-10-29 | 2006-03-02 | 麒麟麦酒株式会社 | Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| CA2501932C (en) | 2002-11-13 | 2014-03-11 | Chiron Corporation | Use of benzimidazole quinolinones for treating cancer |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| AU2003297160A1 (en) | 2002-12-18 | 2004-07-22 | Vertex Pharmaceuticals Incorporated | Benzisoxazole derivatives useful as inhibitors of protein kinases |
| DK1641780T3 (da) | 2003-06-24 | 2009-02-02 | Pfizer Prod Inc | Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater |
| ATE444294T1 (de) * | 2005-10-28 | 2009-10-15 | Irm Llc | Verbindungen und zusammensetzungen als proteinkinaseinhibitoren |
| WO2012052757A1 (en) * | 2010-10-20 | 2012-04-26 | Astrazeneca Ab | Tumour phenotype patient selection method |
| WO2013082499A1 (en) * | 2011-11-30 | 2013-06-06 | Cedars-Sinai Medical Center | Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer |
| JP6407504B2 (ja) | 2012-09-21 | 2018-10-17 | アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法 |
| TWI599356B (zh) | 2012-09-26 | 2017-09-21 | 安羅格製藥有限責任公司 | 抑制突變型ｃ－ｋｉｔ的方法 |
| BR112015016282A2 (pt) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals Inc | crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado |
-
2013
- 2013-07-10 BR BR112015016282A patent/BR112015016282A2/pt not_active Application Discontinuation
- 2013-10-14 CN CN201380069700.XA patent/CN105555272A/zh active Pending
- 2013-10-14 HU HUE13869984A patent/HUE038594T2/hu unknown
- 2013-10-14 SG SG10201705611PA patent/SG10201705611PA/en unknown
- 2013-10-14 SG SG11201505327SA patent/SG11201505327SA/en unknown
- 2013-10-14 CN CN202011110066.8A patent/CN112138010A/zh active Pending
- 2013-10-14 JP JP2015551670A patent/JP6288726B2/ja active Active
- 2013-10-14 SI SI201330974T patent/SI2941251T1/en unknown
- 2013-10-14 RS RS20180287A patent/RS57076B1/sr unknown
- 2013-10-14 PT PT138699848T patent/PT2941251T/pt unknown
- 2013-10-14 EA EA201591290A patent/EA033910B1/ru unknown
- 2013-10-14 KR KR1020157021078A patent/KR101885952B1/ko active IP Right Grant
- 2013-10-14 CN CN201910222133.6A patent/CN109966292A/zh active Pending
- 2013-10-14 AU AU2013371624A patent/AU2013371624B2/en active Active
- 2013-10-14 NZ NZ710720A patent/NZ710720A/en unknown
- 2013-10-14 PL PL13869984T patent/PL2941251T3/pl unknown
- 2013-10-14 PE PE2015001247A patent/PE20151525A1/es not_active Application Discontinuation
- 2013-10-14 DK DK13869984.8T patent/DK2941251T3/en active
- 2013-10-14 US US14/053,011 patent/US9101624B2/en active Active
- 2013-10-14 LT LTEP13869984.8T patent/LT2941251T/lt unknown
- 2013-10-14 WO PCT/US2013/064821 patent/WO2014107209A2/en active Application Filing
- 2013-10-14 EP EP13869984.8A patent/EP2941251B1/en active Active
- 2013-10-14 CA CA2897445A patent/CA2897445C/en active Active
- 2013-10-14 ES ES13869984.8T patent/ES2667958T3/es active Active
- 2013-10-14 CN CN201910222143.XA patent/CN110200970A/zh active Pending
- 2013-10-14 MX MX2015008777A patent/MX369137B/es active IP Right Grant
- 2013-10-14 AP AP2015008628A patent/AP2015008628A0/xx unknown
-
2014
- 2014-07-03 NO NO14742440A patent/NO3019692T3/no unknown
-
2015
- 2015-05-04 US US14/703,500 patent/US9393240B2/en active Active
- 2015-07-06 IL IL239802A patent/IL239802B/en active IP Right Grant
- 2015-07-07 PH PH12015501531A patent/PH12015501531B1/en unknown
- 2015-07-07 CL CL2015001923A patent/CL2015001923A1/es unknown
- 2015-07-31 ZA ZA2015/05545A patent/ZA201505545B/en unknown
-
2016
- 2016-06-28 US US15/195,297 patent/US9801870B2/en active Active
- 2016-11-02 HK HK16112610.7A patent/HK1224211A1/zh unknown
-
2017
- 2017-09-26 US US15/715,274 patent/US10213423B2/en active Active
-
2018
- 2018-03-12 CY CY20181100293T patent/CY1120026T1/el unknown
- 2018-03-22 HR HRP20180478TT patent/HRP20180478T1/hr unknown
-
2019
- 2019-02-22 US US16/282,716 patent/US11007188B2/en active Active
-
2020
- 2020-08-18 US US16/996,400 patent/US11458131B2/en active Active
-
2022
- 2022-08-30 US US17/898,632 patent/US20220409610A1/en active Pending